Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis

INTRODUCTION: Glioblastoma multiforme (GBM) makes 60–70% of gliomas and 15% of primary brain tumors. Despite the availability of standard multimodal therapy, 2 years, 3 years, and 5 years survival rate of GBM are still low. Active immunotherapy is a relatively new treatment option for GBM that seems...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahyuhadi, Joni, Immadoel Haq, Irwan Barlian, Arifianto, Muhammad Reza, Sulistyono, Bagus, Meizikri, Rizki, Rosada, Atika, Sigit Prakoeswa, Cita Rosita, Susilo, Rahadian Indarto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950026/
https://www.ncbi.nlm.nih.gov/pubmed/36748348
http://dx.doi.org/10.1177/10732748221079474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950026/
https://www.ncbi.nlm.nih.gov/pubmed/36748348
http://dx.doi.org/10.1177/10732748221079474

Ejemplares similares